drugset
Drugs / Hyperimmune intravenous immunoglobulin
last change Aug 2013 re-read 2 minutes ago

Hyperimmune intravenous immunoglobulin

Protein / enzyme biologic

Developed for
swine influenza
Investigated by
Caritas Medical Centre, Hong Kong · HK Red Cross Blood Transfusion Service, Hong Kong · Pamela Youde Nethersole Eastern Hospital · Queen Elizabeth Hospital, Hong Kong · Queen Mary Hospital, Hong Kong · Research Fund for the Control of Infectious Diseases, Hong Kong
+3 more · Ruttonjee Hospital, Hong Kong · The University of Hong Kong · United Christian Hospital

Trials 1 · a red edge is where a trial was stopped

today NCT01617317 · not/applicable
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT01617317 Jan 2010 → Nov 2011 swine influenza The University of Hong Kong Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Hyperimmune intravenous immunoglobulin ClinicalTrials.gov intervention name — accepted as the source's own label NCT01617317 ↗
Modality Protein / enzyme biologic “hyperimmune IV immunoglobulin (H-IVIG)” PMID 23450336 ↗ Aug 2013
Route Intravenous “Single intravenous infusion” NCT01617317 ↗